Abiopharma

(99% Neutral) Y-MABS THERAPEUTICS, INC. (YMAB) Announces Regulatory Update

(99% Neutral) Editas Medicine, Inc. (EDIT) Files Form 8-K

(99% Neutral) AERIE PHARMACEUTICALS INC (AERI) Announces Regulatory Update

(99% Neutral) Esperion Therapeutics, Inc. (ESPR) Announces Executive Changes

(10% Negative) Sanofi (SNY) Announces Clinical Development Update (Form 6-K)

(99% Neutral) Landos Biopharma, Inc. (LABP) Files Form 8-K

(10% Negative) HOMOLOGY MEDICINES, INC. (FIXX) Announces Clinical Trial Timeline Adjustment

(19% Negative) CRISPR THERAPEUTICS AG (CRSP) Announces Delay in reductions Trials for transfusion volume Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review, Efficacy Assessment

(99% Neutral) Global Blood Therapeutics, Inc. (GBT) Announces Clinical Development Update

(10% Negative) Keros Therapeutics, Inc. (KROS) Announces Delay in increases Trials for a rodent PAH model Due to Pandemic-Related Challenges, Manufacturing Considerations